489 research outputs found
Recommended from our members
Randomized Controlled Trial of Social Media: Effect of Increased Intensity of the Intervention
Background: A prior randomized controlled trial of social media exposure at Circulation determined that social media did not increase 30‐day page views. Whether insufficient social media intensity contributed to these results is uncertain. Methods and Results: Original article manuscripts were randomized to social media exposure compared with no social media exposure (control) at Circulation beginning in January 2015. Social media exposure consisted of Facebook and Twitter posts on the journal's accounts. To increase social media intensity, a larger base of followers was built using advertising and organic growth, and posts were presented in triplicate and boosted on Facebook and retweeted on Twitter. The primary outcome was 30‐day page views. Stopping rules were established at the point that 50% of the manuscripts were randomized and had 30‐day follow‐up to compare groups on 30‐day page views. The trial was stopped for futility on September 26, 2015. Overall, 74 manuscripts were randomized to receive social media exposure, and 78 manuscripts were randomized to the control arm. The intervention and control arms were similar based on article type (P=0.85), geographic location of the corresponding author (P=0.33), and whether the manuscript had an editorial (P=0.80). Median number of 30‐day page views was 499.5 in the social media arm and 450.5 in the control arm; there was no evidence of a treatment effect (P=0.38). There were no statistically significant interactions of treatment by manuscript type (P=0.86), by corresponding author (P=0.35), by trimester of publication date (P=0.34), or by editorial status (P=0.79). Conclusions: A more intensive social media strategy did not result in increased 30‐day page views of original research
Recommended from our members
An integrated clinical program and crowdsourcing strategy for genomic sequencing and Mendelian disease gene discovery.
Despite major progress in defining the genetic basis of Mendelian disorders, the molecular etiology of many cases remains unknown. Patients with these undiagnosed disorders often have complex presentations and require treatment by multiple health care specialists. Here, we describe an integrated clinical diagnostic and research program using whole-exome and whole-genome sequencing (WES/WGS) for Mendelian disease gene discovery. This program employs specific case ascertainment parameters, a WES/WGS computational analysis pipeline that is optimized for Mendelian disease gene discovery with variant callers tuned to specific inheritance modes, an interdisciplinary crowdsourcing strategy for genomic sequence analysis, matchmaking for additional cases, and integration of the findings regarding gene causality with the clinical management plan. The interdisciplinary gene discovery team includes clinical, computational, and experimental biomedical specialists who interact to identify the genetic etiology of the disease, and when so warranted, to devise improved or novel treatments for affected patients. This program effectively integrates the clinical and research missions of an academic medical center and affords both diagnostic and therapeutic options for patients suffering from genetic disease. It may therefore be germane to other academic medical institutions engaged in implementing genomic medicine programs
Making sense out of massive data by going beyond differential expression
With the rapid growth of publicly available high-throughput transcriptomic data, there is increasing recognition that large sets of such data can be mined to better understand disease states and mechanisms. Prior gene expression analyses, both large and small, have been dichotomous in nature, in which phenotypes are compared using clearly defined controls. Such approaches may require arbitrary decisions about what are considered “normal” phenotypes, and what each phenotype should be compared to. Instead, we adopt a holistic approach in which we characterize phenotypes in the context of a myriad of tissues and diseases. We introduce scalable methods that associate expression patterns to phenotypes in order both to assign phenotype labels to new expression samples and to select phenotypically meaningful gene signatures. By using a nonparametric statistical approach, we identify signatures that are more precise than those from existing approaches and accurately reveal biological processes that are hidden in case vs. control studies. Employing a comprehensive perspective on expression, we show how metastasized tumor samples localize in the vicinity of the primary site counterparts and are overenriched for those phenotype labels. We find that our approach provides insights into the biological processes that underlie differences between tissues and diseases beyond those identified by traditional differential expression analyses. Finally, we provide an online resource (http://concordia.csail.mit.edu) for mapping users’ gene expression samples onto the expression landscape of tissue and disease
Vertrauen in virtuellen Communities: Konzeption und Umsetzung vertrauensunterstützender Komponenten in der Domäne Healthcare
Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside
Despite impressive efforts invested in epigenetic research in the last 50 years, clinical applications are still lacking. Only a few university hospital centers currently use epigenetic biomarkers at the bedside. Moreover, the overall concept of precision medicine is not widely recognized in routine medical practice and the reductionist approach remains predominant in treating patients affected by major diseases such as cancer and cardiovascular diseases. By its’ very nature, epigenetics is integrative of genetic networks. The study of epigenetic biomarkers has led to the identification of numerous drugs with an increasingly significant role in clinical therapy especially of cancer patients. Here, we provide an overview of clinical epigenetics within the context of network analysis. We illustrate achievements to date and discuss how we can move from traditional medicine into the era of network medicine (NM), where pathway-informed molecular diagnostics will allow treatment selection following the paradigm of precision medicine
Discovering hidden relationships between renal diseases and regulated genes through 3D network visualizations
Abstract
Background
In a recent study, two-dimensional (2D) network layouts were used to visualize and quantitatively analyze the relationship between chronic renal diseases and regulated genes. The results revealed complex relationships between disease type, gene specificity, and gene regulation type, which led to important insights about the underlying biological pathways. Here we describe an attempt to extend our understanding of these complex relationships by reanalyzing the data using three-dimensional (3D) network layouts, displayed through 2D and 3D viewing methods.
Findings
The 3D network layout (displayed through the 3D viewing method) revealed that genes implicated in many diseases (non-specific genes) tended to be predominantly down-regulated, whereas genes regulated in a few diseases (disease-specific genes) tended to be up-regulated. This new global relationship was quantitatively validated through comparison to 1000 random permutations of networks of the same size and distribution. Our new finding appeared to be the result of using specific features of the 3D viewing method to analyze the 3D renal network.
Conclusions
The global relationship between gene regulation and gene specificity is the first clue from human studies that there exist common mechanisms across several renal diseases, which suggest hypotheses for the underlying mechanisms. Furthermore, the study suggests hypotheses for why the 3D visualization helped to make salient a new regularity that was difficult to detect in 2D. Future research that tests these hypotheses should enable a more systematic understanding of when and how to use 3D network visualizations to reveal complex regularities in biological networks.http://deepblue.lib.umich.edu/bitstream/2027.42/112972/1/13104_2010_Article_700.pd
Towards a pathway definition of Parkinson’s disease: a complex disorder with links to cancer, diabetes and inflammation
We have previously established a first whole genome transcriptomic profile of sporadic Parkinson’s disease (PD). After extensive brain tissue-based validation combined with cycles of iterative data analysis and by focusing on the most comparable cases of the cohort, we have refined our analysis and established a list of 892 highly dysregulated priority genes that are considered to form the core of the diseased Parkinsonian metabolic network. The substantia nigra pathways, now under scrutiny, contain more than 100 genes whose association with PD is known from the literature. Of those, more than 40 genes belong to the highly significantly dysregulated group identified in our dataset. Apart from the complete list of 892 priority genes, we present pathways revealing PD ‘hub’ as well as ‘peripheral’ network genes. The latter include Lewy body components or interact with known PD genes. Biological associations of PD with cancer, diabetes and inflammation are discussed and interactions of the priority genes with several drugs are provided. Our study illustrates the value of rigorous clinico-pathological correlation when analysing high-throughput data to make optimal use of the histopathological phenome, or morphonome which currently serves as the key diagnostic reference for most human diseases. The need for systematic human tissue banking, following the highest possible professional and ethical standard to enable sustainability, becomes evident
A global view of drug-therapy interactions
Network science is already making an impact on the study of complex systems
and offers a promising variety of tools to understand their formation and
evolution (1-4) in many disparate fields from large communication networks
(5,6), transportation infrastructures (7) and social communities (8,9) to
biological systems (1,10,11). Even though new highthroughput technologies have
rapidly been generating large amounts of genomic data, drug design has not
followed the same development, and it is still complicated and expensive to
develop new single-target drugs. Nevertheless, recent approaches suggest that
multi-target drug design combined with a network-dependent approach and
large-scale systems-oriented strategies (12-14) create a promising framework to
combat complex multigenetic disorders like cancer or diabetes. Here, we
investigate the human network corresponding to the interactions between all US
approved drugs and human therapies, defined by known drug-therapy
relationships. Our results show that the key paths in this network are shorter
than three steps, indicating that distant therapies are separated by a
surprisingly low number of chemical compounds. We also identify a sub-network
composed by drugs with high centrality measures (15), which represent the
structural back-bone of the drug-therapy system and act as hubs routing
information between distant parts of the network. These findings provide for
the first time a global map of the largescale organization of all known drugs
and associated therapies, bringing new insights on possible strategies for
future drug development. Special attention should be given to drugs which
combine the two properties of (a) having a high centrality value and (b) acting
on multiple targets.Comment: 16 pages, 4 figures. It was submitted to peer review on August 15,
200
Drugst.One -- A plug-and-play solution for online systems medicine and network-based drug repurposing
In recent decades, the development of new drugs has become increasingly
expensive and inefficient, and the molecular mechanisms of most pharmaceuticals
remain poorly understood. In response, computational systems and network
medicine tools have emerged to identify potential drug repurposing candidates.
However, these tools often require complex installation and lack intuitive
visual network mining capabilities. To tackle these challenges, we introduce
Drugst.One, a platform that assists specialized computational medicine tools in
becoming user-friendly, web-based utilities for drug repurposing. With just
three lines of code, Drugst.One turns any systems biology software into an
interactive web tool for modeling and analyzing complex protein-drug-disease
networks. Demonstrating its broad adaptability, Drugst.One has been
successfully integrated with 21 computational systems medicine tools. Available
at https://drugst.one, Drugst.One has significant potential for streamlining
the drug discovery process, allowing researchers to focus on essential aspects
of pharmaceutical treatment research.Comment: 45 pages, 6 figures, 7 table
Recent Advances in Systems and Network Medicine:Meeting Report from the First International Conference in Systems and Network Medicine
- …